Guggenheim raises Elevance stock price target to $460 on earnings outlook
Guggenheim raised its price target on Elevance Health (NYSE:ELV) to $460 from $455, citing improved performance in Medicaid, Medicare Advantage, and ACA segments. The firm expects continued earnings growth and maintains a Buy rating. Elevance reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share. Other analysts have mixed views on the stock.
How this was made
The 30-second read
Why it matters
The price target raise signals confidence in earnings recovery, but execution risks remain.
Market read
Analyst target increase may drive short-term buying interest in ELV and influence sector sentiment.
What to watch
Potential regulatory headwinds and execution risk of cost initiatives.
Background
Elevance Health reaffirmed full-year 2026 guidance and announced Medicaid market exits, while analysts adjusted price targets.
Ticker impact
Guggenheim raised its price target on Elevance Health to $460, citing improved Medicaid, Medicare Advantage and ACA outlook.
likely upward pressure as market prices in higher target
Target increase reflects expectations of earnings growth and margin improvement.
Market effects
Health insurer sector may see broader valuation lift from ELV's upgraded outlook.
U.S. equity markets, particularly healthcare index, could benefit.
Limited to U.S. investors; minimal global spillover.
Counterpoint
Target may be overly optimistic given Medicaid market exits and declining Medicare Stars rating.
Key entities
- companyElevance Health Inc.
U.S. health insurer (ticker ELV) subject of analyst price target upgrade.
- analyst_firmGuggenheim
Research firm that raised ELV's price target to $460.
